XML 11 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Organization and Basis of Presentation - (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 22, 2019
USD ($)
Jun. 27, 2019
USD ($)
Jun. 19, 2019
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
Aug. 07, 2019
shares
Dec. 31, 2018
item
Organization and basis of presentation information              
In-process research and development expensed       $ 1,500 $ 3,745    
Proposed acquisition of Avedro, Inc.              
Organization and basis of presentation information              
Number of shares received in connection with Merger for each share of company owned stock | shares           0.365  
Ownership percentage of combined company           85.00%  
Licensing Arrangement with Intratus, Inc.              
Organization and basis of presentation information              
In-process research and development expensed $ 1,500            
Cash payments for the acquisition of certain assets $ 1,500            
DOSE Medical Corporation              
Organization and basis of presentation information              
In-process research and development expensed   $ 2,200          
Period for U.S. Food and Drug Administration (FDA) approval for additional consideration     10 years        
Period for EU European Medicines Agency approval for additional consideration     10 years        
Quarterly royalty rate (as a percent)     5.00%        
Period for the quarterly royalty rate payments     10 years        
Cash payments for the acquisition of certain assets of related party     $ 2,500        
Capitalized property and equipment   $ 300          
DOSE Medical Corporation | Minimum              
Organization and basis of presentation information              
Additional future consideration for U.S. Food and Drug Administration (FDA) approval     5,000        
Additional future consideration for European Medicines Agency approval     1,250        
Additional future consideration for certain net sales milestones     7,500        
Buyout of additional consideration amount     10,000        
DOSE Medical Corporation | Maximum              
Organization and basis of presentation information              
Additional future consideration for U.S. Food and Drug Administration (FDA) approval     22,500        
Additional future consideration for European Medicines Agency approval     2,500        
Additional future consideration for certain net sales milestones     20,000        
Buyout of additional consideration amount     $ 55,000        
Avedro, Inc.              
Organization and basis of presentation information              
Number of procedures performed | item             400,000
Number of procedures performed in the United States | item             18,000
Avedro, Inc. | Proposed acquisition of Avedro, Inc.              
Organization and basis of presentation information              
Ownership percentage of combined company           15.00%